Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH)
Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes
You may not be if
Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease
Has history of type 1 diabetes
Had a bariatric surgical procedure less than 5 years before entry into the study
History of pancreatitis
Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke
Clareo Health | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
